Advertisement

Topics

Latest "Evrogen Joint Stock Company" News Stories

06:46 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Evrogen Joint Stock Company" found in our extensive news archives from over 250 global news sources.

More Information about Evrogen Joint Stock Company on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Evrogen Joint Stock Company for you to read. Along with our medical data and news we also list Evrogen Joint Stock Company Clinical Trials, which are updated daily. BioPortfolio also has a large database of Evrogen Joint Stock Company Companies for you to search.

Showing "Evrogen Joint Stock Company" News Articles 1–25 of 21,000+

Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...


AXOGEN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AxoGen, Inc. - AXGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN), if they purchased the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7...

Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code

Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets. On February 11, 2019, Aradigm determined that without confirmation of funding from their primary investor and partner, the Company would not...


Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antib...

TransCanna Announces Corporate Update Conference Call

Vancouver, British Columbia--(Newsfile Corp. - February 15, 2019) - TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") intends to host a corporate update conference cal...

Stealth Bio’s IPO Raises $78M for Clinical Tests of Mitochondrial Drugs

Stealth BioTherapeutics has popped up on the radar with a $78 million IPO to fund clinical trials for drugs treating rare mitochondrial disorders. Shares of Stealth Bio (NASDAQ: MITO) made their stock market debut Friday at $12 apiece, which was the low end of the company’s targeted $12 to $14 range. The biotech sold 6.5 […]

SurgCenter Development Celebrates New Milestone with Formation of 200th ASC Partnership

SurgCenter Development, developer of ASCs and leader in outpatient total joint replacements, celebrates new milestone with formation of its 200th ASC, SurgCenter of Clearwater. TAMPA, Fla. (PRWEB) February 15, 2019 SurgCenter Development (http://www.surgcenter.com) (SCD), a leader in the development of ambulatory surgical centers (ASCs) throughout the U.S., celebrates the formation of its 200th A...

Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019

Press release Malmö, February 15, 2019 Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursement directly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Acarix was aiming for full reimbursement in Germany by the end of 2...

Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders

                                                                  Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...

Vivacelle Bio, Inc. Receives FDA Clearance to Enroll Patients into its Phase IIa Clinical Trial of VBI-1 for Severe Blood Loss and/or Raising Blood Pressure in Hypovolemic Subjects

Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical trial of the safety and efficacy of VBI-1. VBI-1 is a paradigm-changing cardiovascular support fluid that is designed for the treatment of patients with emergently life-threate...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

Cross Country Healthcare to Present at Barclays Global Healthcare Conference and Oppenheimer’s 29th Annual Healthcare Conference

Cross Country Healthcare, Inc. (Nasdaq: CCRN) announced today that it is scheduled to present at two upcoming conferences: The Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 3:50 p.m. Eastern Time, at the Loews Miami Beach Hotel in Miami Beach, Florida. The Oppenheimer 29th Annual Healthcare Confe...

Tekla Healthcare Investors Declares Stock Distribution

On February 15, 2019, Tekla Healthcare Investors declared a stock distribution of $0.41 per share. The record date for the stock distribution is February 28, 2019 and the payable date is March 29, 2019. The Fund will trade ex-distribution on February 27, 2019. This stock distribution will automatically be paid in newly issued shares of the Fund un...

Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option … Continued The post Hoth Therapeutics Announces ...

Agilent / DSO1072B / Oscilloscope, 70 MHz, 2 Analog Channels

£200.00 (0 Bids)End Date: Sunday Feb-17-2019 18:18:51 GMTBid now | Add to watch list Biotech365 : Agilent / DSO1072B / Oscilloscope, 70 MHz, 2 Analog Channels BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool … Continue reading →

HOOKIPA Appoints Michael A. Kelly as Independent Director.

New York, US and Vienna, Austria – 15 February 2019 – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors. Mr. Kelly is a former senior exe...

Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo(nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from an interim analysis of the Phase 2 CheckMate -650 trial showed that among 32 asymptomatic or minimally symptomatic pat...

Health-E Commerce Receives Majority Equity Investment from Beecken Petty O'Keefe & Company ("BPOC")

Health-E Commerce Is the Parent Company of Leading Health and Wellness E-Commerce Sites FSAstore.com, HSAstore.com and WellDeserved NEW YORK (PRWEB) February 15, 2019 Health-E Commerce, the parent company of the nation’s leading family of e-commerce brands dedicated to pre-tax health and wellness products and services, today announced that it has received a majority equity investment from Beeck...

HOOKIPA Appoints Michael A. Kelly as Independent Director

HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors. Mr. Kelly is a former senior executive of Amgen, Inc. currently acting as Foun...

Pharmalot.. Pharmalittle.. Good Morning.. Company buys drug and raises price 70%, Oklahoma opioid trial is the one to watch & more news.. plus, weekend daydreams.. https://www.statnews.com/pharmalot/2019/02/15/drug-prices-opioids-oklahoma-trial/ … #ph

Pharmalot.. Pharmalittle.. Good Morning.. Company buys drug and raises price 70%, Oklahoma opioid trial is the one to watch & more news.. plus, weekend daydreams.. https://www.statnews.com/pharmalot/2019/02/15/drug-prices-opioids-oklahoma-trial/ … #pharma #drugprices #opioids

STAT Plus: Pharmalittle: Company buys drug and raises price 70 percent; Oklahoma opioid trial is the one to watch

The day after Egalet bought a pain reliever, the company boosted the price by 70 percent, which was the largest single brand price hike in over a year.

Stock price effects of breakthrough therapy designation https://go.nature.com/2X7gcSH  - a new analysis by @Frank_S_David and colleaguespic.twitter.com/xxTpt5yS0U

Stock price effects of breakthrough therapy designation https://go.nature.com/2X7gcSH  - a new analysis by @Frank_S_David and colleagues pic.twitter.com/xxTpt5yS0U

IIP Operating Partnership, LP Prices Private Offering of $125 Million of 3.75% Exchangeable Senior Notes Due 2024

Innovative Industrial Properties, Inc. (the "Company") (NYSE: IIPR) announced today that its operating partnership subsidiary, IIP Operating Partnership, LP (the "Operating Partnership"), priced a private offering of $125 million aggregate principal amount of 3.75% Exchangeable Senior Notes due 2024 (the "Notes"). The Operating ...

Level Brands Provides Corporate Update

Proposals to be voted on at 2019 Annual Meeting Include Corporate Name Change to cbdMD and Expansion of Board of Directors Level Brands, Inc. (NYSE American: LEVB) announced today that the proposals to be considered at the 2019 annual meeting of shareholders scheduled for March 29, 2019 include a change of its corporate name to cbdMD Inc. and the expan...

CPSI Announces Fourth Quarter and Year-End 2018 Results

CPSI (NASDAQ: CPSI): Highlights for Fourth Quarter 2018: Revenues of $72.3 million; TruBridge bookings of $7.8 million; Backlog of $257 million; Total bookings of $23.6 million; GAAP net income of $7.6 million and non-GAAP net income of $10.7 million; ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks